Table 1.
Participant demographic and clinical characteristics.
| Asthma
|
Controls
|
|||
|---|---|---|---|---|
| Normal weight N = 25 |
Overweight N = 25 |
Normal weight N = 25 |
Overweight N = 25 |
|
| Age, mean (SD) | 13.9 (2.5) | 12.4 (1.8) | 14.3 (2.9) | 13.6 (2.9) |
| Male, n (%) | 16 (64.0) | 16 (64.0) | 13 (52.0) | 12 (48.0) |
| BMI in kg/m2, mean (SD) | 19.5 (2.2) | 26.9 (3.1) | 19.4 (2.5) | 27.3 (3.5) |
| Body fat %, mean (SD) | 21.5 (6.5) | 35.6 (6.4) | 21.9 (5.1) | 40.6 (9.3) |
| Height in cm, mean (SD) | 149.5 (12.2) | 147.2 (10.0) | 148.5 (11.2) | 148.7 (11.3) |
| Atopy, n (%) (n = 93) | 24 (96.0) | 18 (72.0) | 13 (52.0) | 14 (56.0) |
| Serum IgE in kU/L, median (IQR) | 1331 (763.2–1971) | 1129 (331–2354) | 176.6 (83.2–557.2) | 296.6 (114.5–1159) |
| Pre-bronchodilator FVC, L (SD) | 3.21 (1.0) | 3.08 (0.7) | 3.07 (0.8) | 3.20 (0.8) |
| Pre-bronchodilator FEV1, L (SD) | 2.71 (0.8) | 2.59 (0.6) | 2.79 (0.7) | 2.85 (0.7) |
| Pre-bronchodilator FEV1/FVC %, mean (SD) | 85.5 (8.5) | 84.6 (7.3) | 91.1 (3.9) | 89.5 (3.1) |
| FEV1 reversibility, n (%) (n = 93) | 3 (12.0) | 5 (20.0) | 0 (0.0) | 0 (0.0) |
| FeNO ppb, median (IQR) | 34 (24–70) | 21 (11–46) | 13 (9–18) | 13 (8–18) |
| ACT score, mean (SD) | 22.9 (3.7) | 22.0 (3.4) | – | – |
| Use of β2-agonist inhalers for crisis control in the last 12 months, n (%) (n = 48) | 3 (12.0) | 9 (36.0) | – | – |
| Use of ICS in the last 12 months, n (%) (n = 48) | 1 (4.0) | 3 (12.0) | – | – |